<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635320</url>
  </required_header>
  <id_info>
    <org_study_id>DPS-201502</org_study_id>
    <secondary_id>2018l0002</secondary_id>
    <nct_id>NCT03635320</nct_id>
  </id_info>
  <brief_title>The CHINA TFNA Study</brief_title>
  <acronym>TFNA</acronym>
  <official_title>A Prospective Study Evaluating Trochanteric Fixation Nail Advanced (TFNA) in a Chinese Patient Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synthes GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson Medical (Shanghai) Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Synthes GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, randomized, controlled, two-arm, non-inferiority study&#xD;
      which will be conducted in China to support registration of a cephalomedullary nailing system&#xD;
      (TFNA) that currently is available globally. The study will compare the safety and the&#xD;
      effectiveness of two intramedullary nails (the investigational group is TFNA and the control&#xD;
      group is PFNA-II).Patients enrolled at each site will be randomized in a ratio of 1:1, i.e.&#xD;
      one patient assigned to surgery implanted with TFNA for each patient assigned to PFNA-II.&#xD;
      Separate block randomization schedules within each site will be used to ensure equal&#xD;
      distribution of treatment and control patients. Up to 15 centers will be approved to&#xD;
      participate in this study.&#xD;
&#xD;
      Patient will be clinically followed after surgery at 1, 6, 12 and 24 weeks. The data up to&#xD;
      and including 24 week follow up visit will be used in determining the primary safety and&#xD;
      effectiveness of the TFNA.&#xD;
&#xD;
      The primary objective of this study is to evaluate whether fracture union rate, evaluated 24&#xD;
      weeks after proximal femur fracture, for the investigational TFNA intramedullary nail is&#xD;
      non-inferior to that for currently available control product PFNA-II in patients with&#xD;
      proximal femur fractures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2018</start_date>
  <completion_date type="Actual">May 18, 2020</completion_date>
  <primary_completion_date type="Actual">May 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study population will include 188 patients with proximal femur fracture undergoing internal fixation using an intramedullary nail.&#xD;
Subjects will be randomized in a 1:1 ratio to receive either the investigational TFNA devices (n=94) or to the control PFNA-II devices (n=94).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Only patient is masked during the study. He/she will be notified during inform consent that either treatment will be used but they will not be informed exactly which group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Successful Fracture Union Rate 24 Weeks After Surgery</measure>
    <time_frame>24 weeks</time_frame>
    <description>The number of achieving fracuture union at 24 weeks of each group will be counted and the percentage will be calculated.&#xD;
Fracture union success is a composite endpoint; in order for an individual subject's surgery implanted with TFNA or PFNA-II to be considered successful he/she must satisfy all of the following criteria:&#xD;
No focal tenderness or lengthwise percussion pain, or abnormal movement&#xD;
The frontal/lateral X-ray examination shows the vague or no fracture gap, or the continuous callus passing across the fracture line&#xD;
No deformation or breakage is found in the test product</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Femur Fractures</condition>
  <arm_group>
    <arm_group_label>investigational group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>using Trochanteric Fixation Nail Advanced to treat the fracture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Using Proximal Femoral Nail Antirotation to treat the fracture</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TFNA</intervention_name>
    <description>intramedullary nail 'Trochanteric Fixation Nail Advanced' to treat proximal femur fracture undergoing internal fixation</description>
    <arm_group_label>investigational group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PFNA-II</intervention_name>
    <description>intramedullary nail ' Proximal Femoral Nail Antirotation' to treat proximal femur fracture undergoing internal fixation</description>
    <arm_group_label>the control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥18 years&#xD;
&#xD;
          2. Patients with unilateral proximal femur fractures that will be treated with&#xD;
             intramedullary nail internal fixation&#xD;
&#xD;
          3. According to AO fracture classification, subjects with following fracture type:&#xD;
&#xD;
               1. Pertrochanteric (31-A1 and 31-A2)&#xD;
&#xD;
               2. Intertrochanteric (31-A3)&#xD;
&#xD;
               3. Trochanteric area (31-A1/A2/A3) with diaphyseal extension&#xD;
&#xD;
          4. Subject must be comfortable with speaking and understanding questions and responses in&#xD;
             an available translated language for patient reported outcomes (PROs)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject does not provide voluntary consent to participate in the study&#xD;
&#xD;
          2. The subject is a woman who is pregnant or lactating&#xD;
&#xD;
          3. Fractures where the operative treatment will occur more than three weeks after the&#xD;
             primary injury&#xD;
&#xD;
          4. Patients with femoral head fractures and femoral neck fractures (AO classification&#xD;
             31-B and 31-C)&#xD;
&#xD;
          5. Pathological fracture (e.g., primary or metastatic tumor)&#xD;
&#xD;
          6. Serious soft tissue injury, judged by the investigator, will impact the union of the&#xD;
             fracture, combined vascular injury, and combined osteofascial compartment syndrome&#xD;
&#xD;
          7. Multiple systemic injuries judged by researchers not suitable for enrollment, or&#xD;
             orthopaedic fractures in other bones at three or more sites&#xD;
&#xD;
          8. Revision surgeries (for example, due to malunion, nonunion or infection)&#xD;
&#xD;
          9. Concurrent medical conditions judged by researchers not suitable for enrollment, such&#xD;
             as: diabetes, metabolic bone disease, post-polio syndrome, poor bone quality, prior&#xD;
             history of poor fracture healing, etc&#xD;
&#xD;
         10. Patients with anaesthetic and surgical contraindications&#xD;
&#xD;
         11. Patients known to be allergic to implant components&#xD;
&#xD;
         12. Patients who are currently using chemotherapeutics or accepting radiotherapy, use&#xD;
             systematically corticosteroid hormone or growth factor, or long-term use sedative&#xD;
             hypnotics (continuous use over 3 months) or non-steroidal anti-inflammatory drugs&#xD;
             (continuous use over 3 months)&#xD;
&#xD;
         13. Intemperance judged by researchers not suitable for enrollment (e.g., excessive daily&#xD;
             drinking or smoking, drug abuse);&#xD;
&#xD;
         14. Patients participated into other clinical trial in the previous 3 months;&#xD;
&#xD;
         15. Patients with bad compliance judged by researchers and cannot complete the test&#xD;
             according to test scheme, such as schizophrenia and dementia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manyi Wang, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Jishuitan Hospita</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vivian Li, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Medical (Shanghai) Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Jishuitan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100035</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical university</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hong Kong shenzhen hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second AffiliatedHospital of Zhejiang University of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Jiangsu</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Nantong University</name>
      <address>
        <city>Nantong</city>
        <state>Nantong</state>
        <zip>226000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <results_first_submitted>March 16, 2021</results_first_submitted>
  <results_first_submitted_qc>April 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 21, 2021</results_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Femoral Fractures</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT03635320/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT03635320/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One hundred eighty-eight subjects were included in this study and randomly assigned to a study group; enrollment included 94 in the study group and 94 in the control group. Subjects were clinically followed after surgery at 1, 6, 12 and 24 weeks at the hospital.</recruitment_details>
      <pre_assignment_details>Subjects required to meet inclustion/exclusion prior to receiving device. 4 subjects were screened but not randomized: 1 subject withdrew ICF before randomization, 1 subject didn't meet inclusion criteria 4, 1 subject met exclusion criteria 9 and 10, 1 subject met exclusion criteria 15.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TFNA Group (Study Group)</title>
          <description>intramedullary nail 'Trochanteric Fixation Nail Advanced' to treat proximal femur fracture undergoing internal fixation</description>
        </group>
        <group group_id="P2">
          <title>PFNA-II Group (Control Group)</title>
          <description>intramedullary nail 'Proximal Femoral Nail Antirotation' to treat proximal femur fracture undergoing internal fixation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>FAS</title>
              <participants_list>
                <participants group_id="P1" count="93">1 subject was not implanted the device</participants>
                <participants group_id="P2" count="92">2 subjects were not implant the device</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>PPS</title>
              <participants_list>
                <participants group_id="P1" count="81">11 subjects early discontinued and didn't complete the trial which were excluded from PPS, 1 subject had a risk of unblinding, which was excluded from the PPS.</participants>
                <participants group_id="P2" count="83">6 subjects early discontinued and didn't complete the trial which were excluded from PPS, 1 subject didn't undergo the evaluation or laboratory examination required by the clinical trial, 1 subject violated the inclusion/exclusion criteria and 1 subject used the device beyond the scope of the specifications, which were excluded from the PPS.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>not implanted the device</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>3 subjects were not implanted with any device, so total 185 subjects were included in FAS.</population>
      <group_list>
        <group group_id="B1">
          <title>TFNA Group (Study Group)</title>
          <description>intramedullary nail 'Trochanteric Fixation Nail Advanced' to treat proximal femur fracture undergoing internal fixation</description>
        </group>
        <group group_id="B2">
          <title>PFNA-II Group (Control Group)</title>
          <description>intramedullary nail 'Proximal Femoral Nail Antirotation' to treat proximal femur fracture undergoing internal fixation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="92"/>
            <count group_id="B3" value="185"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>based on the FAS</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.8" lower_limit="30" upper_limit="91"/>
                    <measurement group_id="B2" value="74.1" lower_limit="29" upper_limit="91"/>
                    <measurement group_id="B3" value="75.9" lower_limit="29" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>based on the FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>based on the FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Han(Asian)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical history</title>
          <population>based on the FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Osteoporosis</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malnutrition</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hormone deficiency</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoke within one year</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drink within one year</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Successful Fracture Union Rate 24 Weeks After Surgery</title>
        <description>The number of achieving fracuture union at 24 weeks of each group will be counted and the percentage will be calculated.&#xD;
Fracture union success is a composite endpoint; in order for an individual subject's surgery implanted with TFNA or PFNA-II to be considered successful he/she must satisfy all of the following criteria:&#xD;
No focal tenderness or lengthwise percussion pain, or abnormal movement&#xD;
The frontal/lateral X-ray examination shows the vague or no fracture gap, or the continuous callus passing across the fracture line&#xD;
No deformation or breakage is found in the test product</description>
        <time_frame>24 weeks</time_frame>
        <population>based on PPS</population>
        <group_list>
          <group group_id="O1">
            <title>TFNA Group (Study Group)</title>
            <description>intramedullary nail 'Trochanteric Fixation Nail Advanced' to treat proximal femur fracture undergoing internal fixation</description>
          </group>
          <group group_id="O2">
            <title>PFNA-II Group (Control Group)</title>
            <description>intramedullary nail 'Proximal Femoral Nail Antirotation' to treat proximal femur fracture undergoing internal fixation</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Fracture Union Rate 24 Weeks After Surgery</title>
          <description>The number of achieving fracuture union at 24 weeks of each group will be counted and the percentage will be calculated.&#xD;
Fracture union success is a composite endpoint; in order for an individual subject's surgery implanted with TFNA or PFNA-II to be considered successful he/she must satisfy all of the following criteria:&#xD;
No focal tenderness or lengthwise percussion pain, or abnormal movement&#xD;
The frontal/lateral X-ray examination shows the vague or no fracture gap, or the continuous callus passing across the fracture line&#xD;
No deformation or breakage is found in the test product</description>
          <population>based on PPS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority margin of -10%</non_inferiority_desc>
            <param_type>95%CI</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.53</ci_lower_limit>
            <ci_upper_limit>4.42</ci_upper_limit>
            <estimate_desc>If the lower limit of 95% CI of the difference in the rates of the study group and the control group is greater than the non-inferiority margin of -10%, then the investigational product is considered non-inferior to the control product.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events and serious adverse events were recorded starting at the time of subject randomization, until subject completion of study (24 weeks follow-up visit after surgery). All AEs were followed until the AE resolved, stabilized, or the study was completed.</time_frame>
      <desc>Judged the relationship between them and the products, and summarized the occurrence types of AEs for the safety evaluation of the product.</desc>
      <group_list>
        <group group_id="E1">
          <title>TFNA Group (Study Group)</title>
          <description>intramedullary nail 'Trochanteric Fixation Nail Advanced' to treat proximal femur fracture undergoing internal fixation</description>
        </group>
        <group group_id="E2">
          <title>PFNA-II Group (Control Group)</title>
          <description>intramedullary nail 'Proximal Femoral Nail Antirotation' to treat proximal femur fracture undergoing internal fixation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device-related</sub_title>
                <description>The Serious Adverse Events which was judged as Device-related Adverse Events</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Non-device related</sub_title>
                <description>The Serious Adverse Events which was judged as Non-device related Adverse Events</description>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="93"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device related</sub_title>
                <description>The Adverse Events which was judged as Device-related Adverse Events</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Non-device related</sub_title>
                <description>The Serious Adverse Events which was judged as Non-device related Adverse Events</description>
                <counts group_id="E1" events="362" subjects_affected="93" subjects_at_risk="93"/>
                <counts group_id="E2" events="361" subjects_affected="89" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal investigator and institution will not be able to publish single-center study data until combined results of the multicenter study are published. If multicenter publication is not performed within 12 months after the end or if sponsor notifies principal investigator and institution in writing that the multicenter study results will not be published, the principal investigator and institution may publish the results of their studies separately in accordance with contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jie, Zhou</name_or_title>
      <organization>Johnson &amp; Johnson Medical (Shanghai) Ltd.</organization>
      <phone>+86 18600551010</phone>
      <email>JZHOU138@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

